Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in treatment-experienced, virologically-suppressed adults living with HIV-1

Eron, J.J.; Orkin, C.; Cunningham, D.; Pulido, F.; Post, F.A.; De Wit, S.; Lathouwers, E.; Hufkens, V.; Jezorwski, J.; Petrovic, R.; Brown, K.; Van Landuyt, E.; Opsomer, M.; De Wit, S.; Florence, E.; Moutschen, M.; Van Wijngaerden, E.; Vandekerckhove, L.; Vandercam, B.; Brunetta, J.; Conway, B.; Klein, M.; Murphy, D.; Rachlis, A.; Shafran, S.; Walmsley, S.; Ajana, F.; Cotte, L.; Girardy, P.-M.; Katlama, C.; Molina, J.-M.; Poizot-Martin, I.; Raffi, F.; Rey, D.; Reynes, J.; Teicher, E.; Yazdanpanah, Y.; Gasiorowski, J.; Halota, W.; Horban, A.; Piekarska, A.; Witor, A.; Arribas, J.R.; Perez-Valero, I.; Berenguer, J.; Casado, J.; Gatell, J.M.; Gutierrez, F.; Galindo, M.J.; Gutierrez, M.D.M.; Iribarren, J.A.; Knobel, H.; Negredo, E.; Pineda, J.A.; Podzamczer, D.; Sogorb, J.P.; Pulido, F.; Ricart, C.; Rivero, A.; Santos Gil, I.; Blaxhult, A.; Flamholc, L.; Gisslèn, M.; Thalme, A.; Fehr, J.; Rauch, A.; Stoeckle, M.; Clarke, A.; Gazzard, B.G.; Johnson, M.A.; Orkin, C.; Ustianowski, A.; Waters, L.; Bailey, J.; Benson, P.; Bhatti, L.; Brar, I.; Bredeek, U.F.; Brinson, C.; Crofoot, G.; Cunningham, D.; DeJesus, E.; Dietz, C.; Dretler, R.; Eron, J.; Felizarta, F.; Fichtenbaum, C.; Gallant, J.; Gathe, J.; Hagins, D.; Henn, S.; Henry, W.K.; Huhn, G.; Jain, M.; Lucasti, C.; Martorell, C.; McDonald, C.; Mills, A.; Morales-Ramirez, J.; Mounzer, K.; Nahass, R.; Olivet, H.; Osiyemi, O.; Prelutsky, D.; Ramgopal, M.; Rashbaum, B.; Richmond, G.; Ruane, P.; Scarsella, A.; Scribner, A.; Shalit, P.; Shamblaw, D.; Slim, J.; Tashima, K.; Voskuhl, G.; Ward, D.; Wilkin, A.; de Vente, J.

doi:10.1016/J.ANTIVIRAL.2019.104543

Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in treatment-experienced, virologically-suppressed adults living with HIV-1

Eron, J.J.
Orkin, C.
Cunningham, D.
Pulido, F.
Post, F.A.
De Wit, S.
Lathouwers, E.
Hufkens, V.
Jezorwski, J.
Petrovic, R.
Brown, K.
Van Landuyt, E.
Opsomer, M.
De Wit, S.
Florence, E.
Moutschen, M.
Van Wijngaerden, E.
Vandekerckhove, L.
Vandercam, B.
Brunetta, J.
Conway, B.
Klein, M.
Murphy, D.
Rachlis, A.
Shafran, S.
Walmsley, S.
Ajana, F.
Cotte, L.
Girardy, P.-M.
Katlama, C.
Molina, J.-M.
Poizot-Martin, I.
Raffi, F.
Rey, D.
Reynes, J.
Teicher, E.
Yazdanpanah, Y.
Gasiorowski, J.
Halota, W.
Horban, A.
Piekarska, A.
Witor, A.
Arribas, J.R.
Perez-Valero, I.
Berenguer, J.
Casado, J.
Gatell, J.M.
Gutierrez, F.
Galindo, M.J.
Gutierrez, M.D.M.
Iribarren, J.A.
Knobel, H.
Negredo, E.
Pineda, J.A.
Podzamczer, D.
Sogorb, J.P.
Pulido, F.
Ricart, C.
Rivero, A.
Santos Gil, I.
Blaxhult, A.
Flamholc, L.
Gisslèn, M.
Thalme, A.
Fehr, J.
Rauch, A.
Stoeckle, M.
Clarke, A.
Gazzard, B.G.
Johnson, M.A.
Orkin, C.
Ustianowski, A.
Waters, L.
Bailey, J.
Benson, P.
Bhatti, L.
Brar, I.
Bredeek, U.F.
Brinson, C.
Crofoot, G.
Cunningham, D.
DeJesus, E.
Dietz, C.
Dretler, R.
Eron, J.
Felizarta, F.
Fichtenbaum, C.
Gallant, J.
Gathe, J.
Hagins, D.
Henn, S.
Henry, W.K.
Huhn, G.
Jain, M.
Lucasti, C.
Martorell, C.
McDonald, C.
Mills, A.
Morales-Ramirez, J.
Mounzer, K.
Nahass, R.
Olivet, H.
Osiyemi, O.
Prelutsky, D.
Ramgopal, M.
Rashbaum, B.
Richmond, G.
Ruane, P.
Scarsella, A.
Scribner, A.
Shalit, P.
Shamblaw, D.
Slim, J.
Tashima, K.
Voskuhl, G.
Ward, D.
Wilkin, A.
de Vente, J.
Mostrar todos os autores +

Revista:

Antiviral Research

ISSN: 1872-9096, 0166-3542

Ano de publicación: 2019

Volume: 170

Tipo: Artigo

DOI: 10.1016/J.ANTIVIRAL.2019.104543 GOOGLE SCHOLAR Acceso aberto editor

Fonte de datos: Scopus